The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

Analysts covering Merck predict earnings growth of 17.6% in 2025 and an additional 10.4% increase in 2026. With shares currently trading at seven times forward 2025 earnings, Merck appears to be an ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5.

Moderna and Merck & Co have expanded their ... as our work with the PD-1-specific antibody Keytruda has shown.” Keytruda (pembrolizumab) was granted a priority review by the US Food and Drug ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Simply put, Keytruda is the far more important growth driver, and the story there is much more exciting. The continued soaring success of Keytruda speaks to the triumphant legacy of Merck’s ...